ClinicalTrials.gg
TerminatedNCT03325491Rejuvenate2Updated Sep 27, 2019

Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance

An interventional study of Acipimox and Placebo in Impaired Mitochondrial Function, Muscle Performance, sponsored by University of Exeter. Terminated at 1 site in United Kingdom. Open to male participants aged 65 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by University of Exeter · Not applicable, Interventional, and Prevention

Why this study was terminated
Challenges recruiting healthy, sedentary 65-75 year old males
Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
Male
01

Study summary

As people grow older skeletal muscle gradually becomes smaller and weaker, causing reduced mobility and quality of life. To understand and reverse this negative process investigators need to find new ways of improving the ability of muscle to perform physical activity. There is some evidence that supplements may improve how the mitochondria work, and investigators want to explore this idea in more detail. This is possible by measuring how the muscles work and respond to exercise before and after taking the supplement alongside an aerobic (i.e. cycling) and resistance (i.e. weight lifting) exercise programme. This will give us the basic information investigators would need to see if this is a useful idea.

02

Conditions studied

  • Impaired Mitochondrial Function, Muscle Performance
03

In context

Lead sponsor

University of Exeter is the lead sponsor of 140 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Age between 65-75 years
  • between 19-29
  • No active cardiovascular or metabolic disease
  • No active respiratory disease
  • No current musculoskeletal injuries
  • A sedentary lifestyle (i.e. does not engage in strenuous, planned physical activity)
  • The ability to give

Exclusion criteria

Exclusion Criteria:

  • Currently taking a statin drug or NSAIDs
  • Have a current peptic ulcer
  • Have any renal impairment
  • Have a known to Acipimox
  • Suffer from vertigo
  • Smoker
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Acipimox plus exercise training

    The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.

    Dietary Supplement: Acipimox

  • Placebo comparator
    Placebo plus exercise training

    The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementAcipimox

    Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.

  • Dietary supplementPlacebo

    Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change in mitochondrial function

    Mitochondria will be extracted from muscle samples immediately post-biopsy (biopsies taken baseline, week 3 and week 6) and analysed for content and subsequently for oxidative respiratory function using the Oroboros technique, and maximal rates of Adenosine Triphosphate (ATP) production.

    Time frame: Baseline, 3 weeks, 6 weeks

Secondary outcomes

  1. Chronic changes in habitual muscle protein synthetic rates

    Baseline saliva samples then frequent saliva samples over 6 weeks following oral ingestion of the stable isotope deuterium oxide (D2O, or 'heavy water') will be analysed by gas-chromatography-pyrolysis-isotope ratio mass-spectrometry. analysis. Muscle samples collected at baseline, 3 weeks, 6 weeks will also be analysed by gas-chromatography-pyrolysis-isotope ratio mass-spectrometry

    Time frame: Baseline, 3 weeks and 6 weeks

07

Study locations

1 site
  • NIHR Exeter Clinical Research Facility
    Exeter, Devon EX2 5DW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03325491
Collaborators
Royal Devon and Exeter NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Mar 7, 2018
Primary completion
Sep 16, 2019
Completion
Sep 16, 2019
Last update
Sep 27, 2019

Study contacts

Colleen Deane, PhD
principal investigator · University of Exeter

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acipimox

Start the discussion